Eylea Sales Continue to Increase; Lucentis Gains New Indications

August 11, 2017: By Joan McKenna

Lucentis and EyleaRegeneron reported that its Q2-2017 net sales of Eylea in the US totaled $919 million, an increase of 11 percent over Q2-2016 net sales of $831 million.

Bayer commercializes Eylea outside the US, and its Q2-2017 net sales of the anti-VEGF increased to $542 million, up 10 percent over $486 million in Q2-2016. Regeneron said it recognized $191 million from its share of Bayer’s Eylea sales, compared with $167 million in Q2-2016.

Roche reported that Lucentis’ Q2-2017 sales in the US totaled about $348 million (CHF $335 million, conversion Aug. 11, 2017), a 5 percent decline from Q2-2016 sales. Still, revenues for the retinal treatment were up 2 percent for the first half of the year at $755 million (CHF $727 million). Roche noted that Lucentis gained US FDA approval for all forms of diabetic retinopathy during the quarter.

Novartis sells Lucentis outside the US, and its Q2-2017 sales totaled $477 million, up 5 percent in constant currency but flat in US dollars. Novartis said Lucentis has gained added labeling for choroidal neovascularization in 51 countries, as well as Europe, where the indication was approved in 2016, and the Lucentis prefilled syringe has launched in 32 countries.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023